Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion Today on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals to Co-Host KOL Panel Discussion on Changes in the Clinical Trial and Treatment Landscape for Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Presents New Data From Phase 2b Study of Eblasakimab in Atopic Dermatitis in Late Breaker Presentation at 32nd European Academy of Dermatology and Venereology Congress
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Announces Acceptance of Late Breaker Abstract on Eblasakimab Phase 2b Results as Oral Presentation and Three Additional Abstracts at 32nd European Academy of Dermatology and Venereology Congress
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy in Positive Phase 2b Study in Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals to Host Webcast on July 6, 2023, to Discuss Phase 2b Topline Data From TREK-AD Trial Evaluating Eblasakimab in Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Announces Publication in Clinical Immunology Highlighting Eblasakimab’s Unique Mechanism of Action in the Treatment of Atopic Dermatitis
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Enters Into a Strategic Licensing Deal With Zenyaku Kogyo for the Development and Commercialization of Eblasakimab in Japan
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Doses First Patient in Phase 2a Trial of Farudodstat in Alopecia Areata
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Presents New Data on Eblasakimab and Farudodstat in Two Late-Breaking Presentations at the 1st International Societies for Investigative Dermatology Meeting
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN TMO
ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Regains Compliance With Nasdaq Listing Requirements
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN TMO
ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals to Host Virtual Research and Development Day on Novel DHODH Inhibitor Farudodstat for Alopecia Areata
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals to Advance Novel DHODH Inhibitor Farudodstat Into Phase 2 Clinical Testing as Potential First-In-Class Treatment for Alopecia Areata
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Announces $20M Private Placement Led by BVF Partners L.P. With the Potential to Receive Up to an Additional $80M
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Announces Completion of Recruitment in Phase 2b TREK-AD Study of Eblasakimab in Atopic Dermatitis Patients
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals and Thermo Fisher Scientific Announce Partnership to Manufacture High Concentration Formulation of Eblasakimab for Future Studies
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN TMO
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
ASLAN Pharmaceuticals Announces First Patient Screened in Study of Eblasakimab in Dupilumab Experienced Atopic Dermatitis Patients
From ASLAN PHARMACEUTICALS LIMITED
Via GlobeNewswire
Tickers ASLN
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.